Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort. Issue 4 (April 2022)

• Record Type: Journal Article
• Authors: Walbi, Ismail A.; Albarqi, Hassan A.; Alghanim, Nayef Saleh; Albadi, Marzooq Abdullah; Al Maimouni, Hesham Mohammed; Alkahtani, Saad Ahmed; Alshabi, Ali Mohamed; Alali, Amer S.; Alqahtani, Faleh; Al-Najjar, Amal Hassan; Hazzazi, Mohammad A; Alanazi, Deemah S; Sabei, Abdulrahman Abdulaziz; Alsaweed, Omer S; Alajra, Rahaf K; Alqhtani, Hussain
• Is Part Of: Journal of international medical research. Volume 50:Issue 4(2022)
• Publication Date: 2022-04
• Subjects: Hydroxychloroquine -- coronavirus disease 2019 -- disease complication -- rheumatoid arthritis -- systemic lupus erythematosus -- severe acute respiratory syndrome coronavirus-2 -- chronic drug use -- drug repurposing; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/03000605221090363
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: Hydroxychloroquine (HCQ) has been used during the coronavirus disease 2019 (COVID-19) pandemic because of its reported anti-viral activity. This study examined the association of chronic HCQ use with the incidence and complications of COVID-19. Methods: This retrospective cohort study included adults with rheumatoid arthritis and/or systemic lupus erythematosus who visited rheumatology clinics in three tertiary hospitals in Riyadh, Saudi Arabia between January 2019 and December 2020. Patients were categorized into two groups based on HCQ use. Data were obtained from the electronic health record and by interviews with patients. The primary study objective was the incidence of COVID-19 and its complications from March 2020 to February 2021. Results: Almost 11% of the study cohort was positive for COVID-19, and the incidence of COVID-19 was similar between HCQ users (11.11%) and nonusers (10.86%). Disease complication rates were similar in the study arms, and they mainly included fever, dry cough, fatigue, and breathing difficulty. Conclusions: This study revealed no significant association between chronic HCQ use and the incidence of COVID-19, and disease complications were similar in the study arms.